查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1363172

泌尿生殖治療藥物的市場規模、佔有率和趨勢分析報告：按適應症、按產品、地區、細分趨勢，2023-2030

Genitourinary Drugs Market Size, Share & Trends Analysis Report By Indication (Prostate, Ovarian, Bladder, Cervical Cancer, UTI & STD), By Product (Hormonal Therapy, Gynecological), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 110 Pages | 商品交期: 2-10個工作天內

價格

泌尿生殖醫學市場的成長與趨勢：

Grand View Research, Inc.的最新報告顯示，預計2023年至2030年全球泌尿生殖藥物市場規模將以1.1%的年複合成長率成長，到2030年將達到317.5億美元。

該領域預計將受到大公司大量研發投資的推動，並導致候選藥物的大規模開發。因此，預計為泌尿生殖疾病提供有效治療選擇的泌尿生殖藥物市場的藥物數量將迅速增加。

此外，不斷增加的藥物召回也加劇了臨床上迫切需要開發具有標靶治療機制的相對較新和先進的藥物。總的來說，這些要素在預測期內為該行業提供了巨大的成長機會。

此外，主要市場參與者在全球的影響力不斷擴大，預計將提高患者和醫生對泌尿生殖系統疾病治療方案的意識層級。預計這將在預測期內進一步擴大泌尿生殖市場的成長潛力。由於學名藥競爭加劇、假藥數量增加以及多項專利即將到期，預計未來年度市場成長將放緩。

泌尿生殖治療市場報告亮點

  • 由於全球罹患率上升，2022年前列腺癌在適應症領域中佔據最大佔有率。據估計，蛋白質體學技術的進步以及篩檢和診斷方法的改進是這種壓倒性市場佔有率的背後原因。
  • 2022年，北美將以超過37.0%的佔有率主導全球泌尿生殖醫學市場。這一主導佔有率是由於該地區的高疾病負擔，預計這將鼓勵研究人員和醫療保健專業人員傾向於先進的配方技術，擴大該領域的成長範圍。
  • 預計亞太地區的年複合成長率在預測期內將超過 4.8%。這種快速成長歸因於醫療保健支出的增加以及主要行業參與者為提高臨床研究和製造設施的基礎設施品質配合措施。
  • 市場參與企業正在透過新產品開拓和合作策略擴大市場佔有率並提高在該領域的影響力。例如，2023年3月，諾華公司透過與Aduro Biotech合作，進一步加強了其癌症免疫療法研究計劃，增加了發現和開發下一代癌症免疫療法的力度。

目錄

第1章 調查方法與範圍

第2章 執行摘要

第3章 泌尿生殖藥物市場的變數、趨勢與範圍

  • 市場體系預測
    • 母市場預測
    • 相關/附隨市場預測
  • 普及和成長預測圖
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 泌尿生殖醫學市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章 泌尿生殖醫學市場：按適應症估計與趨勢分析

  • 泌尿生殖醫學市場：重點
  • 泌尿生殖藥物市場：2022 年和 2030 年趨勢和市場佔有率分析
  • 攝護腺癌
  • 卵巢癌
  • 膀胱癌
  • 子宮頸癌
  • 腎癌
  • 勃起功能障礙
  • 尿道感染
  • 尿失禁和膀胱過動症
  • 性行為感染傳染病
  • 間質性膀胱炎
  • 血尿
  • 良性攝護腺增生症

第5章 泌尿生殖醫學市場：按產品估價及趨勢分析

  • 泌尿生殖醫學市場：重點
  • 泌尿生殖藥物市場：2022 年和 2030 年趨勢和市場佔有率分析
  • 泌尿系統
  • 荷爾蒙治療
  • 婦科
  • 感染疾病
  • 其他

第6章 泌尿生殖醫學市場：區域估計與趨勢分析

  • 區域展望
  • 按地區分類的泌尿生殖藥物市場：重點
  • 北美洲
    • 2018-2030 年市場估計與預測
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 瑞典
    • 挪威
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 市場參與企業分類
    • Abbott
    • Bristol-Myers Squibb Co.
    • Novartis AG
    • Genentech, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Ionis Pharmaceuticals, Inc.
    • Eli Lilly and Company
    • Merck & Co. Inc.
    • Pfizer, Inc.
    • AstraZeneca
    • GlaxoSmithKline
    • Teva Pharmaceutical Industries Ltd.
    • Bayer AG
    • Allergan.
    • Antares Pharma
Product Code: GVR-1-68038-285-3

Genitourinary Drugs Market Growth & Trends:

The global genitourinary drugs market size is expected to reach USD 31.75 billion by 2030, expanding at a CAGR of 1.1% from 2023 to 2030, according to a new report by Grand View Research, Inc.. This sector is expected to be driven by high R&D investments undertaken by the key companies, which is expected to result in the large-scale development of new drug candidates. This is presumed to increase the influx of drugs at a rapid pace into the genitourinary drugs market hence providing efficient treatment alternatives for numerous genitourinary disorders.

In addition, growing incidence of drug recalls is fueling the high clinical urgency to develop relatively new and advanced drugs with targeted therapy mechanisms. These factors cumulatively are slated to present the vertical with considerable growth opportunities over the forecast period.

Furthermore, increasing global presence of the major market players is anticipated to raise the awareness levels pertaining to treatment alternatives for genitourinary diseases amongst the patients as well as the physicians. This is further expected to widen the genitourinary market growth potential during the forecast period. Growing generic drugs competition, rising presence of counterfeit drugs, and with several patent expirations in the horizon, the market growth is expected to slow down over the coming years.

Genitourinary Drugs Market Report Highlights:

  • Prostate cancer held the largest share of the indication segment in 2022 owing to the rising global incidence of the condition. In addition, advances in proteomics technology and improved screening and diagnostic procedures are presumed to be responsible for the dominant share.
  • In 2022, North America dominated the global genitourinary drugs vertical with a share of over 37.0%. The dominant share is attributable to the high disease burden present in this region, thus driving the inclination of researchers and healthcare professionals toward advanced formulation technologies, which is anticipated to widen the growth scope for this sector
  • Asia Pacific is expected to witness a lucrative CAGR of over 4.8% during the forecast period. The exponential growth rate can be attributed to the rising healthcare spending and the improving infrastructure quality of clinical research and manufacturing facilities owing to the initiatives of the key vertical players
  • The prominent participants are employing new product development and collaborative strategies to capture greater market share and increase their presence in this sector. For instance, in March 2023, Novartis AG further enhanced its cancer immunotherapy research initiative through collaboration with Aduro Biotech to increase its activities toward discovery and development in next generation cancer immunotherapy

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Indication
    • 1.1.2. Product
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Indication outlook
    • 2.2.2. Product outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Genitourinary Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
    • 3.3.2. Market Restraint Analysis
  • 3.4. Genitourinary Drugs Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic Landscape

Chapter 4. Genitourinary Drugs Market: Indication Estimates & Trend Analysis

  • 4.1. Genitourinary Drugs Market: Key Takeaways
  • 4.2. Genitourinary Drugs Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Prostate Cancer
    • 4.3.1. Prostate cancer market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Ovarian Cancer
    • 4.4.1. Ovarian cancer market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Bladder Cancer
    • 4.5.1. Bladder cancer market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. Cervical Cancer
    • 4.6.1. Cervical cancer market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7. Renal Cancer
    • 4.7.1. Renal cancer market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.8. Erectile Dysfunction
    • 4.8.1. Erectile dysfunction market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.9. Urinary Tract Infections
    • 4.9.1. Urinary tract infections market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.10. Urinary Incontinence & Overactive Bladder
    • 4.10.1. Urinary incontinence & overactive bladder market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.11. Sexually Transmitted Diseases
    • 4.11.1. Sexually transmitted diseases market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.12. Interstitial Cystitis
    • 4.12.1. Interstitial cystitis market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.13. Hematuria
    • 4.13.1. Hematuria market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.14. Benign Prostatic Hyperplasia
    • 4.14.1. Benign prostatic hyperplasia market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Genitourinary Drugs Market: Product Estimates & Trend Analysis

  • 5.1. Genitourinary Drugs Market: Key Takeaways
  • 5.2. Genitourinary Drugs Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Urologicals
    • 5.3.1. Urologicals market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Hormonal Therapy
    • 5.4.1. Hormonal therapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Gynecological
    • 5.5.1. Gynecological market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.6. Anti-infectives
    • 5.6.1. Anti-infectives market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Genitourinary Drugs Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Genitourinary Drugs Market by Region: Key Takeaway
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.3. France
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.6. Sweden
      • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.7. Norway
      • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.2. China
      • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.3. India
      • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.5. Thailand
      • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. Mexico
      • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7. MEA
    • 6.7.1. Saudi Arabia
      • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. South Africa
      • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. Abbott
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Bristol-Myers Squibb Co.
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Novartis AG
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Genentech, Inc.
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. F. Hoffmann-La Roche Ltd.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Ionis Pharmaceuticals, Inc.
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Eli Lilly and Company
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Merck & Co. Inc.
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. Pfizer, Inc.
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. AstraZeneca
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives
    • 7.2.11. GlaxoSmithKline
      • 7.2.11.1. Company overview
      • 7.2.11.2. Financial performance
      • 7.2.11.3. Product benchmarking
      • 7.2.11.4. Strategic initiatives
    • 7.2.12. Teva Pharmaceutical Industries Ltd.
      • 7.2.12.1. Company overview
      • 7.2.12.2. Financial performance
      • 7.2.12.3. Product benchmarking
      • 7.2.12.4. Strategic initiatives
    • 7.2.13. Bayer AG
      • 7.2.13.1. Company overview
      • 7.2.13.2. Financial performance
      • 7.2.13.3. Product benchmarking
      • 7.2.13.4. Strategic initiatives
    • 7.2.14. Allergan.
      • 7.2.14.1. Company overview
      • 7.2.14.2. Financial performance
      • 7.2.14.3. Product benchmarking
      • 7.2.14.4. Strategic initiatives
    • 7.2.15. Antares Pharma
      • 7.2.15.1. Company Overview
      • 7.2.15.2. Financial performance
      • 7.2.15.3. Product benchmarking
      • 7.2.15.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 3 North America genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 4 North America genitourinary drugs market, by region, 2018 - 2030 (USD Million)
  • Table 5 U.S. genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 6 U.S. genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 7 Canada genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 8 Canada genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 9 Europe genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 10 Europe genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 11 Europe genitourinary drugs market, by region, 2018 - 2030 (USD Million)
  • Table 12 Germany genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 13 Germany genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 14 UK genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 15 UK genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 16 France genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 17 France genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 18 Italy genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 19 Italy genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 20 Spain genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 21 Spain genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 22 Sweden genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 23 Sweden genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 24 Norway genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 25 Norway genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 26 Denmark genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 27 Denmark genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific genitourinary drugs market, by region, 2018 - 2030 (USD Million)
  • Table 31 China genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 32 China genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 33 Japan genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 34 Japan genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 35 India genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 36 India genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 37 Australia genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 38 Australia genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 39 Thailand genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 40 Thailand genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 41 South Korea genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 42 South Korea genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 43 Latin America genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 44 Latin America genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 45 Latin America genitourinary drugs market, by region, 2018 - 2030 (USD Million)
  • Table 46 Brazil genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 47 Brazil genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 48 Mexico genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 49 Mexico genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 50 Argentina genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 51 Argentina genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 52 Middle East and Africa genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 53 Middle East and Africa genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 54 Middle East and Africa genitourinary drugs market, by region, 2018 - 2030 (USD Million)
  • Table 55 South Africa genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 56 South Africa genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 59 UAE genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 60 UAE genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 61 Kuwait genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 62 Kuwait genitourinary drugs market, by product, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Genitourinary drugs: market outlook
  • Fig. 9 Genitourinary Drugs Competitive Insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Genitourinary drugs market driver impact
  • Fig. 15 Genitourinary drugs market restraint impact
  • Fig. 16 Genitourinary drugs market strategic initiatives analysis
  • Fig. 17 Genitourinary drugs market: Indication movement analysis
  • Fig. 18 Genitourinary drugs market: Indication outlook and key takeaways
  • Fig. 19 Prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Ovarian cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Bladder cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Cervical cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Renal cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Erectile dysfunction market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Urinary tract infections market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Urinary incontinence & overactive bladder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Sexually transmitted diseases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Interstitial cystitis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Hematuria market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Benign prostatic hyperplasia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Genitourinary drugs market: Product movement analysis
  • Fig. 32 Genitourinary drugs market: Product outlook and key takeaways
  • Fig. 33 Urologicals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Hormonal therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Gynecological market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Anti-infectives market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Global genitourinary drugs market: Regional movement analysis
  • Fig. 39 Global genitourinary drugs market: Regional outlook and key takeaways
  • Fig. 40 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Europe. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)